By Gina Shaw
Pfizer’s year-end 2016 “soft launch” of infliximab-dyyb (Inflectra), a biosimilar to infliximab (Remicade, Janssen)—the first monoclonal antibody biosimilar—has not yet led to a significant trend toward the biosimilar and away from the innovator product, say specialty pharmacies, payors and others who are keeping a close eye on this high-profile drug class.
Infliximab-dyyb, which began shipping in December, is priced at approximately 10% to 15% less than